Atezolizumab for Idiopathic Pulmonary Fibrosis

Inclusion Criteria: * Males or females ≥50 years of age * Confident diagnosis of IPF per 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline on Diagnosis of IPF1 * Subjects must have a high-resolution computed tomography (HRCT) completed in the 6 months prior to informed consent * Subjects must have HRCT pattern of definite or probable UIP * Subjects without HRCT pattern of definite or probable UIP must have surgical lung biopsy showing histopathology consistent with UIP * Extent of fibrotic changes must be greater than the extent of emphysema on HRCT * Review of all available IPF treatment options with the potential subject prior to consent for participation in the study * Negative hepatitis B surface antigen (HBsAg) test at screening * Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAB test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive total HBcAb test. * Negative hepatitis C antibody * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for 5 months after the final dose of atezolizumab. Women must refrain from donating eggs during this same period. A woman i…